JP2000509041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000509041A5 JP2000509041A5 JP1997538180A JP53818097A JP2000509041A5 JP 2000509041 A5 JP2000509041 A5 JP 2000509041A5 JP 1997538180 A JP1997538180 A JP 1997538180A JP 53818097 A JP53818097 A JP 53818097A JP 2000509041 A5 JP2000509041 A5 JP 2000509041A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63176196A | 1996-04-23 | 1996-04-23 | |
| US08/631,761 | 1996-04-23 | ||
| PCT/US1997/006398 WO1997040011A1 (en) | 1996-04-23 | 1997-04-16 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008060649A Division JP2008247903A (ja) | 1996-04-23 | 2008-03-11 | 中枢神経系障害の予防及び治療のための医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000509041A JP2000509041A (ja) | 2000-07-18 |
| JP2000509041A5 true JP2000509041A5 (enExample) | 2005-12-08 |
| JP4357001B2 JP4357001B2 (ja) | 2009-11-04 |
Family
ID=24532629
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53818097A Expired - Fee Related JP4357001B2 (ja) | 1996-04-23 | 1997-04-16 | 中枢神経系障害の予防及び治療のための医薬組成物 |
| JP2008060649A Pending JP2008247903A (ja) | 1996-04-23 | 2008-03-11 | 中枢神経系障害の予防及び治療のための医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008060649A Pending JP2008247903A (ja) | 1996-04-23 | 2008-03-11 | 中枢神経系障害の予防及び治療のための医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6603011B1 (enExample) |
| EP (2) | EP0900200B9 (enExample) |
| JP (2) | JP4357001B2 (enExample) |
| AT (1) | ATE416164T1 (enExample) |
| AU (1) | AU727976B2 (enExample) |
| BR (1) | BR9708815B1 (enExample) |
| CA (1) | CA2252515C (enExample) |
| DE (1) | DE69739142D1 (enExample) |
| DK (1) | DK0900200T5 (enExample) |
| ES (1) | ES2318856T4 (enExample) |
| PT (1) | PT900200E (enExample) |
| WO (1) | WO1997040011A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6166048A (en) * | 1999-04-20 | 2000-12-26 | Targacept, Inc. | Pharmaceutical compositions for inhibition of cytokine production and secretion |
| US6979695B2 (en) * | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| US20020052497A1 (en) | 2000-03-09 | 2002-05-02 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| AU2880699A (en) | 1998-04-02 | 1999-10-25 | R.J. Reynolds Tobacco Company | Pharmaceutical compositions and methods for use |
| US20050131034A1 (en) | 1998-06-16 | 2005-06-16 | Caldwell William S. | Compounds capable of activating cholinergic receptors |
| EP1086082B9 (en) * | 1998-06-16 | 2005-03-02 | Targacept, Inc. | Arylsubstituted olefinic amines and their use as cholinergic receptors agonists |
| US7790757B2 (en) | 1998-06-16 | 2010-09-07 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| US6232316B1 (en) | 1998-06-16 | 2001-05-15 | Targacept, Inc. | Methods for treatment of CNS disorders |
| US6455734B1 (en) * | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| AU2005201609B2 (en) * | 1999-04-20 | 2007-10-18 | Targacept, Inc | Pharmaceutical compositions for inhibition of cytokine production and secretion |
| US20010031771A1 (en) | 1999-05-24 | 2001-10-18 | Gary Maurice Dull | Pharmaceutical compositions and methods for use |
| EP1185514A1 (en) * | 1999-06-07 | 2002-03-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| NZ516888A (en) * | 1999-07-30 | 2004-02-27 | Vertex Pharma | Acyclic and cyclic amine derivatives |
| WO2001082978A2 (en) * | 2000-05-01 | 2001-11-08 | Targacept, Inc. | Imaging of nicotinic acetylcholine receptor subtypes |
| AU2003258754A1 (en) * | 2002-04-16 | 2003-11-11 | Rhodia Chimie | Aminated compounds bearing at least an allyl and a difluoromethyl and method used for synthesis thereof |
| FR2838436A1 (fr) * | 2002-04-16 | 2003-10-17 | Rhodia Chimie Sa | Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese |
| FR2847578A1 (fr) * | 2002-11-21 | 2004-05-28 | Rhodia Chimie Sa | Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese |
| ATE442822T1 (de) * | 2004-04-02 | 2009-10-15 | Arterial Remodelling Technolog | Stentanordnung auf polymerbasis |
| UA88792C2 (ru) * | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
| US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
| TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型 |
| EP2357174A1 (en) | 2006-05-09 | 2011-08-17 | AstraZeneca AB | Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine |
| CL2007002684A1 (es) * | 2006-09-15 | 2008-06-27 | Astrazeneca Ab Targacept Inc | Combinacion que comprende un antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina; composicion farmaceutica que la comprende; kit farmaceutico; y uso para tratar perjuicio cognitivo y/o trastorno psicoticos. |
| US20100028447A1 (en) * | 2007-01-22 | 2010-02-04 | Targacept, Inc. | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs |
| EP2647373A1 (en) | 2008-05-12 | 2013-10-09 | Targacept, Inc. | Methods for preventing the development of retinopathy by the oral administration of exo-S-mecamylamine. |
| WO2010080757A2 (en) | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
| US8703802B2 (en) | 2010-05-20 | 2014-04-22 | Targacept, Inc. | Process for the preparation of aryl substituted olefinic amines |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965074A (en) | 1985-03-05 | 1990-10-23 | Ciba-Geigy Corporation | Method of treating memory impairment |
| US4684654A (en) * | 1985-08-14 | 1987-08-04 | American Cyanamid Company | 3-heteroalkyl-2,4-quinzaolinediones |
| US4927838A (en) * | 1987-07-10 | 1990-05-22 | Hoffman-La Roche Inc. | Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors |
| US4786646A (en) * | 1987-07-10 | 1988-11-22 | Hoffmann-La Roche Inc. | Cyclopropylpropenamides |
| US4788206A (en) * | 1987-07-10 | 1988-11-29 | Hoffmann-La Roche Inc. | Pentadieneamides |
| US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
| US5210076A (en) | 1988-09-13 | 1993-05-11 | Berliner David L | Methods of treating Parkinson's disease using melanin |
| US5356906A (en) | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
| DE4102289A1 (de) | 1991-01-26 | 1992-07-30 | Bayer Ag | Verfahren zur herstellung von (hetero)arylalk(en/in)-ylaminen und neue (hetero)arylkinylamine |
| JP3153551B2 (ja) | 1991-05-29 | 2001-04-09 | アボツト・ラボラトリーズ | 認識機能を高めるイソオキサゾールおよびイソチアゾール化合物 |
| US5212188A (en) | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
| US5242935A (en) | 1992-03-06 | 1993-09-07 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5227391A (en) | 1992-04-10 | 1993-07-13 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5723477A (en) | 1994-11-10 | 1998-03-03 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5616707A (en) | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
| US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| AU4610896A (en) * | 1995-01-06 | 1996-07-24 | R.J. Reynolds Tobacco Company | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
| US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
-
1997
- 1997-04-16 DE DE69739142T patent/DE69739142D1/de not_active Expired - Lifetime
- 1997-04-16 EP EP97921232A patent/EP0900200B9/en not_active Expired - Lifetime
- 1997-04-16 JP JP53818097A patent/JP4357001B2/ja not_active Expired - Fee Related
- 1997-04-16 DK DK97921232T patent/DK0900200T5/da active
- 1997-04-16 AU AU27332/97A patent/AU727976B2/en not_active Ceased
- 1997-04-16 EP EP08014695A patent/EP1997806A1/en not_active Withdrawn
- 1997-04-16 ES ES97921232T patent/ES2318856T4/es not_active Expired - Lifetime
- 1997-04-16 AT AT97921232T patent/ATE416164T1/de active
- 1997-04-16 CA CA002252515A patent/CA2252515C/en not_active Expired - Fee Related
- 1997-04-16 BR BRPI9708815-3A patent/BR9708815B1/pt not_active IP Right Cessation
- 1997-04-16 PT PT97921232T patent/PT900200E/pt unknown
- 1997-04-16 WO PCT/US1997/006398 patent/WO1997040011A1/en not_active Ceased
-
2000
- 2000-08-21 US US09/642,351 patent/US6603011B1/en not_active Expired - Fee Related
-
2001
- 2001-10-09 US US09/973,419 patent/US6555684B2/en not_active Expired - Fee Related
-
2008
- 2008-03-11 JP JP2008060649A patent/JP2008247903A/ja active Pending